Suppr超能文献

一种新型口服营养补充剂与标准护理相比可改善老年人(或有营养不良风险者)的步速和线粒体功能:一项随机对照试验的结果。

A novel oral nutritional supplement improves gait speed and mitochondrial functioning compared to standard care in older adults with (or at risk of) undernutrition: results from a randomized controlled trial.

机构信息

Division of Human Nutrition and Health, Wageningen University, Wageningen, The Netherlands.

出版信息

Aging (Albany NY). 2021 Apr 2;13(7):9398-9418. doi: 10.18632/aging.202912.

Abstract

Undernutrition in older adults is mainly addressed by oral nutritional supplements, which do not affect physical functioning. In this study, we tested a novel oral nutritional supplement that included whey and casein protein, ursolic acid, free branch-chained amino acids and vitamin D against a standard supplement. We included older adults (>65y) with (or at risk of) undernutrition (n=82) and randomized them to 12 weeks of novel or standard supplement. Both groups showed significant increases in body mass. No within or between-group differences in lean body mass were observed. Fat mass increased significantly more in the standard than the novel supplement group (time*treatment effect P=0.045). The novel supplement group showed a larger improvement in walking performance on distances of 4m (treatment x time interaction P=0.048) and 400m (treatment x time interaction P=0.038) than the standard treatment group. Gene sets related to mitochondrial functioning and oxidative phosphorylation were upregulated in the novel supplement group and downregulated in the standard supplement group. We conclude that a 12-week intervention with the novel supplement improved walking performance both during short and long distance as compared to a standard supplement, which can largely be explained by increased mitochondrial functioning in the group receiving the novel supplement.

摘要

老年人的营养不良主要通过口服营养补充剂来解决,而这些补充剂不会影响身体机能。在这项研究中,我们测试了一种新型的口服营养补充剂,该补充剂包含乳清蛋白和酪蛋白、熊果酸、游离支链氨基酸和维生素 D,与标准补充剂进行了对比。我们纳入了有(或有风险)营养不良的老年人(>65 岁)(n=82),并将他们随机分为新型或标准补充剂组,进行 12 周的治疗。两组的体重均显著增加。未观察到两组间或组内的去脂体重差异。与新型补充剂组相比,标准补充剂组的脂肪量增加更为显著(时间*处理效果 P=0.045)。新型补充剂组在 4m(治疗 x 时间交互作用 P=0.048)和 400m(治疗 x 时间交互作用 P=0.038)的行走距离上的行走表现改善更大,优于标准治疗组。新型补充剂组的与线粒体功能和氧化磷酸化相关的基因集上调,而标准补充剂组的下调。我们得出结论,与标准补充剂相比,新型补充剂的 12 周干预可改善短距离和长距离的行走表现,这在很大程度上可以解释为新型补充剂组的线粒体功能增强。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b2ce/8064187/f1fcfd452eb0/aging-13-202912-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验